Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3992-3997

  Shao, Yu Yun ^a,b   Huang, Chien Chung ^a   Lin, Shiou Der ^a   Hsu, Chih Hung ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SORAFENIB; UFT;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD SAMPLING; CANCER CONTROL; CANCER PROGNOSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METRONOMIC DRUG ADMINISTRATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, METRONOMIC; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SERUM; TEGAFUR; TREATMENT OUTCOME;

EID: 84863940804     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2853     Document Type: Article

References (32)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
2. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47. (Pubitemid 46220849)
3. Norstedt G, Levinovitz A, Moller C, Eriksson LC, Andersson G. Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 1988;9:209-13. (Pubitemid 18037981)
4. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, et al. Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000;87:118-21. (Pubitemid 30368424)
5. Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 2012;38:292-302.
6. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62. (Pubitemid 40897844)
7. Sohda M, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, et al. The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer. Anticancer Res 2004;24:3029-34. (Pubitemid 39407182)
8. MaJ, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
9. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530-42.
10. Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML, et al. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal 2010;24:195-200.
11. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 2002;95:2539-45. (Pubitemid 35424040)
12. Masoodi M, Aghazadeh R, Somi MH, Shavakhi A, Shabestari AA, Zali MR. Serum insulin-like growth factor-I and tumor size in patients with metastatic liver cancer. Hepatitis Monthly 2008;8:179-83.
13. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9.
14. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 2011;80:373-81.
15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
17. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010;53:126-31.
18. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010;102:981-6.
19. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010;116:4590-6.
20. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36. (Pubitemid 38745528)
21. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43. (Pubitemid 35424084)
22. Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:699-708. (Pubitemid 44337930)
23. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-56.
24. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
25. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002;277:48403-9. (Pubitemid 35470797)
26. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006;66:6264-70.
27. Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, et al. Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 2007;26:3920-9. (Pubitemid 46884295)
28. Beckert S, Farrahi F, Perveen Ghani Q, Aslam R, Scheuenstuhl H, Coerper S, et al. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem Biophys Res Commun 2006;341:67-72. (Pubitemid 43117387)
29. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 2012;11:649-59.
30. Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002;8:3259-69. (Pubitemid 35155039)
31. Gariboldi MB, Ravizza R, Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 2010;80:455-62.
32. Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, et al. Inhibition of insulin-like growth factor-I receptor (IGFIR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 2008;44:1577-86.